Investigating how tissue damage leads to a specific type of skin cancer.
Official title: Tissue Damage-Driven Squamous Cell Carcinoma
Funded at University of Wisconsin-Madison · NIH-11293811 · Data updated 2026-11-12
This study is looking at how skin cancer develops in people with a rare genetic condition called Recessive Dystrophic Epidermolysis Bullosa (RDEB), to find out what causes it and how to improve treatment options for those affected.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project start | March 1, 2025 |
| Project end | December 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $245,704 |
| NIH project number | 7R01CA244522-06 |
| Project ID | NIH-11293811 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with Recessive Dystrophic Epidermolysis Bullosa who are at risk of developing squamous cell carcinoma.
✕Less likely to help
Patients with squamous cell carcinoma not associated with tissue damage or those without the genetic condition RDEB may not benefit from this research.
What this research studies
This research focuses on squamous cell carcinoma (SCC), a type of skin cancer that can be deadly, particularly in patients with a rare genetic condition called Recessive Dystrophic Epidermolysis Bullosa (RDEB). The study aims to understand the genetic and environmental factors that contribute to the development and progression of SCC in these patients. By analyzing the tumor microenvironment and gene expression patterns, researchers hope to identify common mechanisms that drive cancer initiation and poor outcomes. This could lead to better predictions of cancer behavior and potential new treatment strategies.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and treatment options for patients with squamous cell carcinoma, particularly those with RDEB.
How similar studies have gone: Other research has shown promising results in understanding the mechanisms of squamous cell carcinoma in different contexts, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University of Wisconsin-Madison
Madison, United States Active
Researchers
- Principal investigator: South, Andrew — University of Wisconsin-Madison
- Study coordinator: South, Andrew
Related research
Other NIH-funded projects on the same topics.
-
Novel idea: Epstein-Barr virus and eye cancer in people living with HIV in Zimbabwe
A study explores whether Epstein-Barr virus could cause a type of eye cancer in people living with HIV in Zimbabwe.
-
Oral cancer recurrence predictor using tumor microbes and gene activity
This NIH grant explores how bacteria and immune signals inside oral cancer tumors relate to whether the cancer comes back, with the aim of making a practical risk predictor for patients.
-
Data-driven classification of aggressive tissue traits to predict cancer outcomes in HPV-negative head and neck cancer
A clinician-science grant uses data science and AI to identify tissue patterns in HPV-negative head and neck cancer that may predict how long patients stay cancer-free.
-
Targeting PIPKIγi5 to boost immune responses against head and neck cancer
A study to see if blocking a specific enzyme, PIPKIγi5, can make head and neck cancer more visible to the immune system and more responsive to existing immunotherapies.
-
Targeted approaches for lung squamous cell carcinoma with key gene changes
A study at a major university is exploring new targets in lung squamous cell carcinoma to help people with this cancer find better treatments.
-
Baculovirus-based therapy to treat head and neck cancer with a gentle, minimally invasive approach
A new, minimally invasive approach using baculovirus-delivered CRISPR gene editing aims to treat head and neck squamous cell carcinoma while aiming to preserve essential tissues.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.